Enterprise Value

2.429B

Cash

209.8M

Avg Qtr Burn

N/A

Short % of Float

25.74%

Insider Ownership

9.55%

Institutional Own.

59.37%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

TG-1801 (anti-CD47/anti-CD19) Details
B-cell malignancies, Cancer, B-cell lymphoma

Phase 1

Data readout

TG-1701 (BTK inhibitor) Details
Chronic lymphocytic leukemia, Cancer

Phase 1

Data readout

Failed

Discontinued

Umbralisib (PI3K-delta & CK1-epsilon inhibitor) + Ublituximab (CD20) Details
R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia)

Failed

Discontinued